0OCQ.LSE Transgene SA
- Market cap
- EUR 47.1M
- P/E
- -
- P/B
- -
- ROE
- -57.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0OCQ.LSE undervalued?
Graham numberThe Graham number of Transgene SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Transgene SA fundamental analysis
No fundamental analysis for Transgene SA yet.
Transgene SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical tr…
Full company profileTransgene SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Transgene SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.35M | 2.10M | 1.34M | 6.65M | 2.98M | 9.99M | 3.13M | 7.90M | 35.0K | 137K | 12.0M |
| Gross Profit | 309K | -6.40M | -26.0M | -24.7M | -24.4M | -22.9M | -29.0M | -21.7M | -27.9M | 490K | -49.7M |
| Operating Income | -30.2M | -33.9M | -33.0M | -31.9M | -30.9M | -30.3M | -37.0M | -30.0M | -42.0M | -41.1M | -77.8M |
| EBITDA | -26.7M | -32.7M | -26.0M | -22.1M | -20.4M | -23.6M | -37.2M | -28.4M | -37.0M | -39.8M | -75.0M |
| Net Income | -25.2M | -32.3M | 8.03M | -18.8M | -17.2M | -19.5M | -32.8M | -22.3M | -34.0M | -37.5M | -62.7M |
| EPS | -0.44 | -0.51 | 0.12 | -0.23 | -0.21 | -0.21 | -0.33 | -0.22 | -0.29 | -0.26 | -0.23 |
| Balance Sheet | |||||||||||
| Total Assets | 123M | 101M | 109M | 115M | 85.5M | 102M | 66.4M | 45.2M | 42.2M | 139M | 125M |
| Total Liabilities | 59.2M | 53.3M | 51.5M | 37.9M | 22.2M | 21.9M | 17.5M | 29.6M | 27.0M | 17.1M | 15.3M |
| Shareholders' Equity | 46.5M | 28.1M | 36.7M | 65.7M | 50.3M | 67.2M | 37.8M | 15.6M | 15.2M | 122M | 109M |
| Cash & Short-term Investments | 56.2M | 41.4M | 16.9M | 43.4M | 26.4M | 49.6M | 26.8M | 15.7M | 16.7M | 112M | 92.8M |
| Total Debt | 18.8M | 18.5M | 18.9M | 16.3M | 5.01M | 3.73M | 13.5M | 17.3M | 10.2M | 2.06M | 2.18M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -33.6M | -35.4M | -28.1M | -23.4M | -28.9M | -32.1M | -20.9M | -35.0M | -23.8M | -36.7M | -78.1M |
| Capital Expenditure | 47.0K | 462K | 1.40M | 1.73M | 852K | 686K | 1.54M | 2.67M | 3.07M | 842K | 2.55M |
| Free Cash Flow | -33.6M | -35.8M | -29.5M | -25.1M | -29.7M | -32.8M | -22.5M | -37.3M | -26.9M | -37.6M | -80.7M |
| Ratios | |||||||||||
| ROE | -54.2% | -114.9% | 21.9% | -28.6% | -34.3% | -29.1% | -86.7% | -143.0% | -223.4% | -30.8% | -57.4% |
| ROA | -20.5% | -32.0% | 7.4% | -16.3% | -20.2% | -19.2% | -49.4% | -49.4% | -80.5% | -27.0% | -50.3% |
| Net Profit Margin | -1,074.5% | -1,537.6% | 601.4% | -282.7% | -578.0% | -195.5% | -1,049.4% | -282.6% | -97,060.0% | -27,389.8% | -523.5% |
| Debt to Equity | 0.40x | 0.66x | 0.52x | 0.25x | 0.10x | 0.06x | 0.36x | 1.11x | 0.67x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Transgene SA dividends
Transgene SA has not paid dividends in the last 9 fiscal years.
Who owns Transgene SA
- Insiders 80.78%
- Institutions 0.00%
- Public & others 19.22%
- Shares outstanding 62.3M
- Free float 49.0M
Transgene SA company profile
- Company name
- Transgene SA
- Ticker
- 0OCQ.LSE
- ISIN
- FR0005175080
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 152
- Fiscal year end
- December
- Address
- 400, boulevard Gonthier d?Andernach, Illkirch-Graffenstaden, France, 67405
- Phone
- 33 3 88 27 91 00
- Website
- transgene.com
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Transgene SA management
10- Dr. Alessandro Riva M.D.CEO & Chairman of the Board · born 1960
- Ms. Lucie LarguierVP & Chief Financial Officer · born 1984
- Dr. Simone Silva Steiner Ph.D.Chief Technical Officer · born 1976
- Ms. Katell Bidet HuangInterim CSO & Head of Translational Medicine
- Mr. John Felitti J.D., LLMVP, General Counsel & Corporate Secretary · born 1970
- Ms. Christelle SchwoererHuman Resources Director · born 1992
- Mr. James Wentworth M.B.A., Ph.D.VP & Chief Business Officer · born 1980
- Ms. Emmanuelle Dochy M.D.VP of Medical Affairs & Chief Medical Officer · born 1976
- Dr. Anne Stehlin Ph.D.Chief Quality Officer & Responsible Pharmacist · born 1976
- Ms. Gaelle StadtlerVP & Director of Human Resources · born 1984